Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.55 |
| ▸ | ERN1 | O75460 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 13/20 | 0.40 |
| ▸ | BRD2 | P25440 | 4/20 | 0.40 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10200524 | 0.77 | MAP4K4 (0.56) | MAP4K4JAK2BRD4BRD2HSP90AB1 | |
| SCHEMBL8784588 | 0.70 | MAP4K4 (0.69) | MAP4K4BRD4BRD2HSP90AB1 | |
| SCHEMBL19880348 | 0.68 | APP (0.55) | — | |
| SCHEMBL15836992 | 0.66 | MAP4K4 (0.47) | MAP4K4JAK2BRD4 | |
| SCHEMBL5218211 | 0.66 | MAP4K4 (0.66) | MAP4K4JAK2BRD4BRD2DYRK1A | |
| SCHEMBL5888090 | 0.66 | MAP4K4 (0.66) | MAP4K4JAK2BRD4BRD2DYRK1A | |
| SCHEMBL19314123 | 0.65 | HSD17B1 (0.55) | — | |
| SCHEMBL5218215 | 0.65 | MAP4K4 (0.64) | MAP4K4JAK2BRD4BRD2CREBBP | |
| SCHEMBL15815842 | 0.65 | MAP4K4 (0.49) | MAP4K4JAK2BRD4BRD2BRD3 | |
| SCHEMBL8994752 | 0.65 | SNCA (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569336-B2 | Compounds for the treatment of inflammatory disorders | TONG LING (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569336-B2 | Compounds for the treatment of inflammatory disorders | TONG LING (US) | 2013-10-29 | — | — | US | disclosed |
| US-20120015926-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TONG LING (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015926-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TONG LING (US) | 2012-01-19 | — | — | US | disclosed |
| WO-2010054278-A2 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION (US) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015926-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TNF, ADAMTS1, ADAMTS7 | MAP4K4 3120/4885ERN1 2641/4885JAK2 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.